Possible mechanisms contributing to oxidative inactivation of activated protein C: Molecular dynamics study

Summary

Activated protein C (APC) is a serine protease, an effector enzyme of the natural anticoagulant pathway. APC is approved for treatment of severe sepsis characterized by the increased concentrations of H₂O₂ and hypochlorite. We found that treatment of APC with these oxidants markedly inhibits the cleavage of the APC-specific chromogenic substrate, suggesting that oxidants can induce changes in the structure of the active site of APC. Resistance of oxidant-treated APC to chemical digestion with cyanogen bromide (CNBr) implies that methionine oxidation can at least in part be responsible for inhibition of APC. Since methionine residues, the main targets of oxidants in APC, are not included in the active site, we hypothesize that oxidation induces allosteric changes in the architecture of the catalytic triad of APC. Using molecular dynamics (MD) simulations we found that methionine oxidation alters the distance between cSer 195Oγ and cHis57 Nε2 atoms placing them in positions unfavorable for the catalysis. At the same time, neither distances between Cα atoms of the catalytic triad cAsp102-cHis57-cSer195, nor the overall structure of APC changed significantly after oxidation of the methionine residues. Disruption of the H-bond between Nδ1 of cHis57 and carboxyl group of cAsp 102, which can take place during the hypochlorite-induced modification of cHis57,dramatically changed the architecture of the catalytic triad in oxidized APC. This mechanism could contribute to APC inactivation by hypochlorite concurrently with methionine oxidation. These are novel findings, which describe potentially pathophysiologically relevant changes in the functional stability of APC exposed to the oxidative stress.

Keywords

Gla-domain proteins - oxidative stress - protein function / activity

• References

• 1 Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006; 32 (Suppl. 01) 49-60.
• 2 Joyce DE. et al. Leukocyte and endothelial cell interactions in sepsis: relevance of the protein C pathway. Crit Care Med 2004; 32 (Suppl. 05) S280-S286.
• 3 Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR 1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005; 105: 3178-3184.
• 4 Finigan JH. et al. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005; 280: 17286-17293.
• 5 Dhainaut JF. et al. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Crit Care Med 2003; 31: 2291-2301.
• 6 Campbell EJ. et al. Proteolysis by neutrophils. Relative importance of cell-substrate contact and oxidative inactivation of proteinase inhibitors in vitro. J Clin Invest 1982; 70: 845-852.
• 7 Pattison DI. Davies MX Kinetic analysis of the role of histidine chloramines in hypochlorous acid mediated protein oxidation. Biochemistry 2005; 44: 7378-7387.
• 8 Ramafi GJ. et al. Pro-oxidative interactions of cobalt with human neutrophils. Inhal Toxicol 2004; 16: 649-655.
• 9 Stief TW, Heimburger N. Inactivation of serine proteinase inhibitors (serpins) in human plasma by reactive oxidants. Biol Chem Hoppe Seyler 1988; 369: 1337-1342.
• 10 Vogt W, Hesse D. Oxidants generated by the myeloperoxidase-halide system activate the fifth component of human complement, C5. Immunobiology 1994; 192: 1-9.
• 11 Wallaert B. et al. Oxidative inactivation of alpha 1-proteinase inhibitor by alveolar macrophages from healthy smokers requires the presence of myeloperoxidase. Am J Respir Cell Mol Biol 1991; 05: 437-144.
• 12 Wood MJ. et al. Structural and functional consequences of methionine oxidation in thrombomodulin. Biochim Biophys Acta 2005; 1703: 141-147.
• 13 Hausdorf G. et al. Oxidation of a methionine residue in subtilisin-type proteinases by the hydrogen peroxide/borate system—an active site-directed reaction. Biochim Biophys Acta 1988; 952: 20-26.
• 14 Shao B. et al. Methionine sulfoxide and proteolytic cleavage contribute to the inactivation of cathepsin G by hypochlorous acid: an oxidative mechanism for regulation of serine proteinases by myeloperoxidase. J Biol Chem 2005; 280: 29311-29321.
• 15 De Cristofaro R, Landolfi R. Oxidation of human alpha-fhrombin by the myeloperoxidase-H202-chlor-ide system: structural and functional effects. Thromb Haemost 2000; 83: 253-261.
• 16 Yamaji K. et al. Activated protein C, a natural anticoagulant protein, has antioxidant properties and inhibits lipid peroxidation and advanced glycation end products formation. Thromb Res 2005; 115: 319-325.
• 17 Bode W. et al. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-in-hibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci 1992; 01: 426-171.
• 18 Mather T. et al. The 2.8 A crystal structure of Gladomainless activated protein C. EMBO J 1996; 15: 6822-6831.
• 19 Carter P. et al. Probing the mechanism and improving the rate of substrate-assisted catalysis in subtilisin BPN'. Biochemistry 1991; 30: 6142-6148.
• 20 Moult J. et al. Electron density calculations as an extension of protein structure refinement. Streptomyces griseus protease A at 1.5 A resolution. J Mol Biol 1985; 182: 555-566.
• 21 Dodson G, Wlodawer A. Catalytic triads and their relatives. Trends Biochem Sci 1998; 23: 347-352.
• 22 Huber R. et al. Structure of the complex formed by bovine trypsin and bovine pancreatic trypsin inhibitor. II. Crystallographic refinement at 1.9 A resolution. J Mol Biol 1974; 89: 73-101.
• 23 Kale L. et al. NAMD2: Greater scalability for parallel molecular dynamics. J Computational Physics 1999; 151: 283-312.
• 24 Darden T. et al. Particle mesh Ewald: An N- log(N) method for Ewald sums in large systems. J Chem Phys 1993; 89: 10089-10092.
• 25 Darden T. et al. A smooth particle mesh Ewald method. J Chem Phys 1995; 103: 8577-8592.
• 26 MacKerell JrA. et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem 1998; 102: 3286-3616.
• 27 Reitsma PH. et al. Protein C deficiency: a database of mutations. For the Protein C & S Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1993; 69: 77-84.
• 28 Jas GS, Kuczera K. Free-energy simulations of the oxidation of c-terminal methionines in calmodulin. Proteins 2002; 48: 257-268.
• 29 Ryckaert J-P. et al. Numerical Integration of the Cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes. J Comp Phys 1977; 23: 327-341.
• 30 Jorgensen W. et al. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983; 79: 926-935.
• 31 Humphrey W. et al. VMD-Visual Molecular Dynamics. J Mol Graphics 1996; 14: 33-38.
• 32 Lindahl E. et al. GROMACS 3.0: A package for moleculae simulation and trajectory analysis. J Mol Mod 2001; 07: 306-317.
• 33 Test ST, Weiss SJ. Quantitative and temporal characterization of the extracellular H202 pool generated by human neutrophils. J Biol Chem 1984; 259: 399-405.
• 34 Maier KL. et al. Analysis of methionine sulfoxide in proteins. Methods Enzymol 1995; 251: 455-161.
• 35 Sanner MF Python: A Programming Language for Software Integration and Development. J Mol Graphics Mod. 1999 17. 57-61.
• 36 Sanner MF. et al. Reduced surface: an efficient way to compute molecular surfaces. Biopolymers 1996; 38: 305-320.
• 37 Levine RL. et al. Methionine residues as endogenous antioxidants in proteins. Proc Natl Acad Sci USA 1996; 93: 15036-15040.
• 38 Hawkins CL. et al. Hypochlorite-induced oxidation of amino acids, peptides and proteins. Amino Acids 2003; 25: 259-274.
• 39 Bachovchin WW. et al. Nitrogen-15 NMR spectroscopy of the catalytic-triad histidine of a serine protease in peptide boronic acid inhibitor complexes. Biochemistry 1988; 27: 7689-7697.
• 40 Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967; 27: 157-162.
• 41 Rezaie AR, Esmon CT. Conversion of glutamic acid 192 to glutamine in activated protein C changes the substrate specificity and increases reactivity toward macromolecular inhibitors. J Biol Chem 1993; 268: 19943-19948.
• 42 Iengar P, Ramakrishnan C. Knowledge-based modeling of the serine protease triad into non-proteases. Protein Eng 1999; 12: 649-656.
• 43 Rezaie AR, Esmon CT. Molecular basis of residue 192 participation in determination of coagulation protease specificity. Eur J Biochem 1996; 242: 477-184.